Sangamo Therapeutics (SGMOQ) Accounts Payables (2010 - 2025)

Sangamo Therapeutics' Accounts Payables history runs 16 years deep, the most recent figure standing at $14.4 million for Q4 2025.

• On a quarterly basis, Accounts Payables fell 6.77% year-over-year to $14.4 million in Q4 2025; TTM through Dec 2025 was $14.4 million, a 6.77% decrease from a year earlier, with the FY2025 full-year figure at $14.4 million, down 6.77% from the prior year.
• Accounts Payables retreated to $14.4 million in Q4 2025 per SGMOQ's latest filing, from $15.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $22.4 million in Q4 2022 and bottomed at $8.0 million in Q3 2021.
• The 5-year median for Accounts Payables is $15.4 million (2023), against an average of $14.8 million.
• Across the five-year window, Accounts Payables slumped 55.4% in 2021 and soared 129.72% in 2022, its largest moves.
• Year by year, Accounts Payables stood at $9.8 million in 2021, then surged by 129.72% to $22.4 million in 2022, then plunged by 31.93% to $15.3 million in 2023, then grew by 1.48% to $15.5 million in 2024, then decreased by 6.77% to $14.4 million in 2025.
• Per Business Quant, the three latest SGMOQ Accounts Payables figures stand at $14.4 million (Q4 2025), $15.6 million (Q3 2025), and $10.7 million (Q2 2025).